Do we really need a stent in long SFA lesions? No: DEB is the answer
|
|
|
- Albert Bell
- 5 years ago
- Views:
Transcription
1 Do we really need a stent in long SFA lesions? No: DEB is the answer Thomas Zeller, MD University Heart-Center Freiburg-Bad Krozingen Bad Krozingen Germany
2 My Disclosures: Advisory Board: Medtronic-Invatec, W.L. Gore, Angioslide, Medtronic-Ardian, Covedian-ev3 Consulting Fees/Honoraria: Sanofi-Aventis, C.R. Bard, J&J Cordis, Covedian-ev3, Boston Scientific, Straub Medical, Invatec, Biotronik, Optimed, Pathway Medical, W.L. Gore Research Grants: Cook, Krauth Medical, Pathway Medical, Abbott Vascular, J&J Cordis, Angioslide, Ardian, Biotronik, Invatec, InnoRa, W.L. Gore
3 One of the first SFA Recanalizations by Andreas Grüntzig
4 Balloon-Angioplasty Patency baseline post 2 years Gallino A et al. Circulation 1984;70:
5 SIAH Subintimal Angioplasty
6 Recanalization of SFA CTOs Subintimal Angioplasty Sidhu et al.: 120 patients with TASC II C/D lesions Technical success: 91% Primary 6 months patency: 90% Primary 12 months patency: 73% Secondary 12 months patency: 85% 1-year limb salvage: 98% No relevant complications Kim et al.: 63 consecutive procedures / 54 pts. (TASC C 21%, TASC D 79%) Technical success: 94% Primary 12 months patency: 52% Independant predictors for patency: Short occlusion length (p=0,04) Lesion does not involve distal SFA (p=0,006) Number of patent run-off vessels (p=0,018) Sidhu R et al. Vasc Endovascular Surg Nov;44(8): Kim SJ et al. Circ J. 2010;74(9):
![PACT PTX 3µgr/mm 2 + Urea PASSEO 18 LUX PTX 3µgr/mm 2 + BTHC ADVANCE PTX PTX 3µgr/mm 2 NO Excipient CVI PTX / Excipient (?) [1] G.Tepe et al.](/docs-images/94/119146474/images/7-3.jpg "- NEJM 2008; [2] M.Werk et al. - Circulation 2008; [3] D.Scheinert - TCT 2012 oral presentation; [4] M.Werk et al. - Circulation CI 2012; [5] D.")
7 DEB in SFA Evidence: Proof-of-Concept 7 Trials / 6 DEB Technologies; 6-month LLL (Primary Endpoint) PACCOCATH PTX 3µgr/mm 2 + Ultravist LUTONIX PTX 2µgr/mm 2 + Polysorbate & Sorbitol IN.PACT PTX 3µgr/mm 2 + Urea PASSEO 18 LUX PTX 3µgr/mm 2 + BTHC ADVANCE PTX PTX 3µgr/mm 2 NO Excipient CVI PTX / Excipient (?) [1] G.Tepe et al. - NEJM 2008; [2] M.Werk et al. - Circulation 2008; [3] D.Scheinert - TCT 2012 oral presentation; [4] M.Werk et al. - Circulation CI 2012; [5] D.Scheinert EuroPCR 2012 oral presentation; [6] D.Scheinert LINC 2013 oral presentation; [7] S.Duda EuroPCR 2013 oral presentation
8 DEB vs. DES Femoro-Politeal Lesions Bad Krozingen retrospective analysis of 228 patients treated with DEB (131) and DES (97) from May 2009 to Oct 2011 for: Caludication and Rest Pain Femoropoliteal lesions > 10 cm de-novo and restenotic (non-isr)
9 DEB vs. DES Femoro-popliteal Lesions IN.PACT Admiral (Medtronic) Drug: Paclitaxel Excipient: Urea DEB : 4 7 mm DEB Lengths: mm ZILVER PTX (Cook) Drug: Paclitaxel Excipient: none DES : 6 8 mm DES Lenghts: mm
10 Methods Propensity Score Analysis allows for apples-to-apples comparison under nonrandomized condition (minimize differences between treatment groups due to imbalance of baseline covariates) allows balancing of covariates to make more valid inferences about treatment effects Five propensity score groups used for stratification to remove 90% of bias from confounding variable (Cochran, 1968). In each stratum, comparison made as treatments are compared within like patients patients with similar propensity scores.
11 Baseline Patient Characteristics Patient DEB DES p N Age (mean±sd) 68.9 ± ± Male 58.8% (77/131) 63.9% (62/97) Diabetes 40.5% (53/131) 38.1% (37/97) End Stage Renal Disease 1.5% (2/131) 2.1% (2/97) Renal Insufficiency (Cr>1.2 mg/dl) 22.1% (29/131) 18.6% (18/97) Hyperlipidemia 84.0% (110/131) 81.4% (79/97) Past/current smoker 68.7% (90/131) 68.0% (66/97) Hypertension 83.2% (109/131) 80.4% (78/97) ABI (mean±sd) ± ±
12 Baseline Lesion Characteristics Lesion DEB DES p N Location: Proximal SFA 50.4% (66/131) 52.6% (51/97) Mid SFA 70.2% (92/131) 79.4% (77/97) Distal SFA 76.3% (100/131) 86.6% (84/97) P1 26.0% (34/131) 17.5% (17/97) P2 10.7% (14/131) 0.0% (0/97) < P3 7.6% (10/131) 0.0% (0/97) Mean Length (mean±sd) ± ± Length Min / Max (mm) 100, , 350 Restenotic lesions 51.9% (68/131) 44.3% (43/97) Tot Occlusions 52.7% (69/131) 62.9% (61/97) % Diameter Stenosis (mean±sd) 93.5 ± ± Calcification: none 31.3% (41/131) 20.6% (20/97) slight 25.2% (33/131) 48.5% (47/97) moderate 23.7% (31/131) 21.6% (21/97) severe 19.8% (26/131) 9.3% (9/97) 0.527
13 Procedural Characteristics Lesion DEB DES p N Sub-intimal 8.4% (11/131) 17.5% (17/97) Re-entry device used 4.6% (6/131) 9.3% (9/97) pre-dilatation 76.3% (100/131) Provisional Stenting 18.3% (24/131) Refractory Stenosis 3.8% (5/131) Flow-limiting Dissection 9.9% (13/131) Other 4.6% (6/131)
14 12-month Freedom from Death and TLR* Major Adverse Events DEB DES p adjusted p Clinical driven TLR 15.6% (17/109) 19.0% (15/79) p= (mean lesion length 19 cm) * Clinically Driven TLR
15 12-month Freedom from Death and TLR* (DEB ± prov. Stent sub-analysis) (mean lesion length 19 cm) * Clinically Driven TLR
16 1-Year Primary Patency Major Adverse Events DEB DES p adjusted p Binary Restenosis 76.1% (83/109) 69.6% (55/79) p= (mean lesion length 19 cm)
17 1-Year Primary Patency (DEB ± prov. Stent sub-analysis) (mean lesion length 19 cm)
18 DEB Long SFA LEIPZIG Registry Real world Registry of long (24 cm) femoro-popliteal lesions Prospective Multicenter Randomized Corelab Adj. Peer-rev. Published # Limbs 288 Subject Population Major Indication Primary Endpoint Key baseline / proced. characteristics IC + CLI Fem-pop de-novo + ISR 12-month Primary Patency Mean l. length: 24 cm; CTO: 65.3%; ISR: 37.2% Stent rate: 23.3% ( 75% focal) 400-day Primary Patency: 77.6% (fem-pop) 82.4% (SFA only) Key Findings: Very promising (interim) results of IN.PACT DEB in TASC C-D fem-pop lesions pre Atherectomy / Thrombectomy may even further improve DEB results A. Schmidt LINC 2013
![DEB vs. PTA Meta-analysis meta-analysis of DEB vs. PTA: 4 proof-of-concept RCTs / 433 Patients [1] ; median FU = 10.](/docs-images/94/119146474/images/19-1.jpg "3 months DEB shows superior efficacy vs.")
19 DEB vs. PTA Meta-analysis meta-analysis of DEB vs. PTA: 4 proof-of-concept RCTs / 433 Patients [1] ; median FU = 10.3 months DEB shows superior efficacy vs. PTA in angiographic and clinical restenosis and same safety profile DEB significantly reduce TLR, restenosis and LLL vs. PTA no differences in all cause mortality 1. Cassese S et al. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials. Circ Cardiovasc Interv Aug 1;5(4):582-9.
20 DEB vs. BMS (indirect) meta-analysis 11 RCTs / 1464 Patients [1] Median FU = 24m (DEB) 12m (BMS) both DEB and BMS show superior antirestenotic efficacy to PTA DEB is at least as efficacious as BMS without safety trade-offs 1. Fusaro M et al. Paclitaxel-coated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: A metaanalysis of randomized trials versus uncoated balloon and an adjusted indirect comparison. Int J Cardiol Jul 23
21 DEB in Long Femoro-popliteal Lesions Conclusions DEBs potentially overcome the Achille s heel of reduced durability of endovascular revascularisation With the limitations of a retrospective single center study, the advanced Propensity Score statistical method adds rigor and reliability to head-to-head comparisons of real-world cohorts with ~90% of bias removed from confounding variables IN.PACT Admiral and Zilver PTX offer similar safety and efficacy outcomes to patients treated for claudication and rest pain due to long ( 19 cm) SFA lesions DEBs offer a broader anatomical applicability and bring all the advantages of a leave nothing behind first-line therapy
22 RCT: REAL PTX Trial Drug Coated Balloons vs. Zilver PTX DES 3 subgroups stratified to lesion length 1-10 cm cm cm Started enrollment 12/ /150 pts. enrolled after 3 months of stopping recruitment due to Zilver PTX stent recall
Efficacy of DEB in Calcification and Subintimal Angioplasty
Efficacy of DEB in Calcification and Subintimal Angioplasty Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC Div of Cardiovascular Intervention and Research Cardiovascular Center, Korea University
Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD
Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD Associate Professor of Vascular Surgery University of New South Wales Sydney,
Making BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD
Making BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD Faculty Disclosure Thomas Zeller, MD For the 12 months preceding this presentation, I disclose the following types of
Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD
Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD Asan Medical Center, Heart Institute, University of Ulsan College of Medicine, Werk et al. Circulation Cardiovasc Intervent 2012
Are DES and DEB worth the cost in BTK interventions?
Are DES and DEB worth the cost in BTK interventions? Thomas Zeller, MD University Heart-Center Freiburg-Bad Krozingen Bad Krozingen, Germany -1- My Disclosures: Advisory Board: Medtronic-Invatec, Gore,
One Year after In.Pact Deep: Lessons learned from a failed trial. Prof. Dr. Thomas Zeller
One Year after In.Pact Deep: Lessons learned from a failed trial Prof. Dr. Thomas Zeller Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: x Consulting:
DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes
DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes Carlos Mena, MD FACC FSCAI Associate Professor of Medicine - Cardiology Director Cardiac
The importance of scientific evidence. Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern
The importance of scientific evidence Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner... I have the following potential
Latest Insights from the LEVANT II study and sub-group analysis
Latest Insights from the LEVANT II study and sub-group analysis Prof. Dr. med. Dierk Scheinert Division of Interventional Angiology University-Hospital Leipzig, Germany Conflicts of Interest Advisory Board
Long Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA
Long Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA Disclosures John R. Laird Within the past 12 months, I or my spouse/partner have had a
12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort. Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany
12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany Disclosure Speaker name: Gunnar Tepe I have the following potential conflicts
Disclosures. In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA
In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA Disclosures No financial disclosures. Cameron M. Akbari, MD, MBA, FACS Site Director, Vascular Surgery Medstar
COMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions. Dierk Scheinert
COMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions Dierk Scheinert Department of Angiology University Hospital Leipzig, Germany Disclosure
Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort
Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort a.o. Univ. Prof. Dr. Marianne Brodmann Medical University of Graz Graz,
DCB in my practice: How the evidence influences my strategy. Yang-Jin Park
DCB in my practice: How the evidence influences my strategy Yang-Jin Park Associate Professor Division of Vascular Surgery, Department of Surgery Samsung Medical Center Sungkyunkwan University School of
Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry
Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry Marianne Brodmann, MD Head of the Clinical Division of Angiology Department of Internal Medicine Medical University
DCB level 1 evidence review
DCB level 1 evidence review Raphaël COSCAS Vascular Surgery Department Ambroise Paré Hospital, AP-HP and Paris-Ouest University Boulogne-Billancourt, France Disclosure Speaker name: Raphael COSCAS I have
Maximizing Outcomes in a complex population with Drug-coated balloon
Maximizing Outcomes in a complex population with Drug-coated balloon March 13, 2018 Chumpol Wongwanit, MD Siriraj Hospital, Mahidol University, Bangkok, Thailand LINC Asia-Pacific 2018, Hong Kong Disclosure
Clinical benefits on DES Patient s perspectives
Clinical benefits on DES Patient s perspectives Dr. Skyi Pang Vascular Surgeon Department of Surgery Pamela Youde Nethersole Eastern Hospital Hong Kong Disclosure Speaker name: Skyi Pang... I have the
BIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort
BIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort Prof. Dr. Gunnar TEPE, Klinikum Rosenheim, Germany CCI on behalf of the BIOLUX P-III Investigators Disclosure
Could a combination of DCB + stent be the answer in complex SFA lesions
Could a combination of DCB + stent be the answer in complex SFA lesions Sven Bräunlich, MD Division of Interventional Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich
Dierk Scheinert, MD. Department of Angiology University Hospital Leipzig, Germany
The RANGER clinical trial programme: 12-month results from the RANGER RCT and first look at the COMARE I study of RANGER vs. IN.PACT for femoropopliteal lesions Dierk Scheinert, MD Department of Angiology
Current Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis
Current Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis Osamu Iida, MD From the Kansai Rosai Hospital Cardiovascular Center, Amagasaki City, Japan. ABSTRACT: Approximately
DCB + BMS is not a DES
DCB + BMS is not a DES Fabrizio Fanelli, MD, EBIR Professor of Radiology Director Vascular and Interventional Radiology Department "Careggi " University Hospital Florence - Italy Disclosures Consultant
Which Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA
Which Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA Brian DeRubertis, MD, FACS Associate Professor of Surgery UCLA Division
Fabrizio Fanelli, MD, EBIR Director Vascular and Interventional Radiology Department "Careggi " University Hospital Florence - Italy
Don t Use Risky and Embolizing Drug Coated Balloons Below The Knee! Fabrizio Fanelli, MD, EBIR Director Vascular and Interventional Radiology Department "Careggi " University Hospital Florence - Italy
Merits and demerits of DES, DEB or covered stent in lower extremity arterial occlusive disease 성균관의과대학삼성서울병원순환기내과최승혁
Merits and demerits of DES, DEB or covered stent in lower extremity arterial occlusive disease 성균관의과대학삼성서울병원순환기내과최승혁 Contents DES in SFA DES in BTK DEB in SFA DEB in BTK Current status of covered stent
Drug- Coated Balloons for the SFA: Overview of Technology and Results
Drug- Coated Balloons for the SFA: Overview of Technology and Results NCVH Latin American 2015 Bogota, Colombia April 9-11, 2015 Brian G. DeRubertis, M.D. Associate Professor of Surgery Division of Vascular
Real PTX RCT: 3 year data from a randomized comparison of DCB vs. DES in femoropopliteal lesions
Real PTX RCT: 3 year data from a randomized comparison of DCB vs. DES in femoropopliteal lesions Dierk Scheinert, MD Department of Angiology University of Leipzig, Germany Disclosure Dierk Scheinert, MD
DCB + stent in the SFA
DCB + stent in the SFA 12-month results of the Biolux4ever trial Dr. Marc Bosiers LINC 2017, Leipzig Conflict of interest have the following potential conflicts of interest to report: Consulting Employment
Is a Stent or Scaffold Necessary in The SFA?
1 2 3 Is a Stent or Scaffold Necessary in The SFA? Stents were developed to optimize acute results after angioplasty Specifically, stents are universally accepted to manage flow limiting dissections and
Long-term results with interwoven nitinol stents vs. BMS vs. DCB
Long-term results with interwoven nitinol stents vs. BMS vs. DCB Dierk Scheinert, MD Division of Interventional Angiology University Hospital Leipzig, Germany Disclosure Advisory Board /Consultant: Abbott,
MEET M. Bosiers K. Deloose P. Peeters. SFA stenting in 2009 : The good and the ugly What factors influence patency?
MEET 2009 SFA stenting in 2009 : The good and the ugly What factors influence patency? M. Bosiers K. Deloose P. Peeters 1 TASC II 2007 vs TASC 2000 Type A Type B Type C Type D 2000 < 3 cm 3-5 cm < 3 cm
Are Drug-coated balloons Durable? Level 1 evidence review. Koen Keirse, MD Vascular Surgery, RZ Tienen Tienen, Belgium
Are Drug-coated balloons Durable? Level 1 evidence review Koen Keirse, MD Vascular Surgery, RZ Tienen Tienen, Belgium Disclosure Speaker name: Koen Keirse, MD I have the following potential conflicts of
Rotarex mechanical thrombectomythe first line option for thrombotic occlusions?
Rotarex mechanical thrombectomythe first line option for thrombotic occlusions? Dierk Scheinert, MD Division of Interventional Angiology University Hospital Leipzig, Germany Disclosure Advisory Board /Consultant:
DEB in Periphery: What we Know Till Now
DEB in Periphery: What we Know Till Now Karl-Ludwig Schulte Vascular Center Berlin Ev. Hospital Königin Elisabeth St. Gertrauden Hospital Charité, CC13, Humboldt-University Berlin www.vascular-center-berlin.com
Endovascular Therapy vs. Open Femoral Endarterectomy Rationale and Design of the Randomized PESTO Trial
Endovascular Therapy vs. Open Femoral Endarterectomy Rationale and Design of the Randomized PESTO Trial Prof. Thomas Zeller, MD Department Angiology Clinic for Cardiology and Angiology II University Heart-Center
Michael K. W. Lichtenberg MD, FESC on behalf of KANSHAS 1 investigators; Tepe G, Müller-Hülsbeck S, Deloose K, Verbist J, Goverde P, Zeller T
Interim 30-day analysis from the KANSHAS 1 study of the novel KANSHAS drug coated balloon for treatment of femoropopliteal occlusive disease; a latest first-in-human study Michael K. W. Lichtenberg MD,
Treatment Strategies for Long Lesions of greater than 20 cm
Treatment Strategies for Long Lesions of greater than 20 cm Donald L. Jacobs, MD C. Rollins Hanlon Professor and Chair Chair of the Department of Surgery Saint Louis University Disclosure Speaker name:
Michael K.W. Lichtenberg, MD
Ranger All-Comer Registry Treatment of femoropopliteal atherosclerotic lesions using the Drug eluting Balloon Ranger: An All Comers Registry Michael K.W. Lichtenberg, MD Klinikum Arnsberg Arnsberg, Germany
Final Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
Potential Conflicts of Interest
DES-BTK: A Prospective, Double-Blind Randomized Trial of Polymer-Free Sirolimus-Eluting Stents Compared to Bare Metal Stents in Patients with Infrapopliteal Disease Aljoscha Rastan, MD, Gunnar Tepe, MD,
Combination therapy : treatment rationale and clinical evidence
LINC Asia Pacific 2016, Hong Kong A.Z. Sint-Blasius, Dendermonde Marc Bosiers Koen Deloose Joren Callaert Imelda Hospital, Bonheiden Patrick Peeters Jürgen Verbist Combination therapy : treatment rationale
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Dr. Sven Bräunlich Department of Angiology University-Hospital Leipzig, Germany Disclosure Speaker
Update from Korea on the Lutonix SFA registry 12 month data
Update from Korea on the Lutonix SFA registry 12 month data Prospective, Multicenter, Post-Market Registy Assessing the Clinical Use and Safety of the Lutonix Drug Coated Balloon in Femoropopliteal Arteries
Disclosures. Rational Selection of Endovascular Options for the SFA and Popliteal: What Works Where and for How Long?
Rational Selection of Endovascular Options for the SFA and Popliteal: What Works Where and for How Long? UCSF Vascular Symposium 2017 April 6-8, 2017 San Francisco, CA Disclosures Consulting, Speakers
Final Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
6-month 0utcomes of a Novel Sirolimus Coated DCB Technology Evaluated in SFA Thomas Zeller, MD University Heart Center Freiburg-Bad Krozingen
First Report of the SELUTION Trial: 6-month 0utcomes of a Novel Sirolimus Coated DCB Technology Evaluated in SFA Thomas Zeller, MD University Heart Center Freiburg-Bad Krozingen On behalf of the SELUTION
Update on the Levant 2 Clinical Trial Programme. Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany
Update on the Levant 2 Clinical Trial Programme Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany Disclosure Speaker name: Dierk Scheinert I have the following potential conflicts of interest
Lessons learnt from DES in the SFA is there any ideal concept so far?
Wednesday, January 25, 2017 - Time: 11:49-11:55 DEEP DIVE SESSION: Lower limb interventions (part II) Lessons learnt from DES in the SFA is there any ideal concept so far? S.Müller-Hülsbeck, MD, EBIR,
BioMimics 3D in my Clinical Practice
BioMimics 3D in my Clinical Practice M Lichtenberg M.D. Vascular Centre Arnsberg / German Venous Centre Arnsberg CAUTION: Investigational Device. Limited by Federal (or United States) Law to Investigational
Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease?
Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease? The REALITY trial G. Torsello Münster Disclosure Speaker name: G. Torsello... I have
Christian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide
2-Year Results Of The Tack Optimized Balloon Angioplasty (TOBA) Trial For Fem- Pop Lesions Demonstrates Safety and Efficacy Of The Tack Endovascular System In Repairing Focal Post-PTA Dissections Christian
4/14/2016. Faculty Disclosure. Drug-eluting technology in the SFA and Popliteal. Typical SFA Disease Pattern. Why Peripheral Artery Disease Matters
Drug-eluting technology in the SFA and Popliteal David Paul Slovut, MD, PhD Associate Professor of Medicine and Surgery Co-director of TAVR program Director of Advanced Intervention Faculty Disclosure
BIOFLEX PEACE Registry
BIOFLEX PEACE Registry Pulsar Efficacy: an All Comers Registry INTERIM ANALYSIS Michael K. W. Lichtenberg On behalf of the BIOFLEX-PEACE study group Definition and understanding of various radial forces
Update on the role of drug eluting balloons
Update on the role of drug eluting balloons William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular Research
Drug delivery devices for BTK treatment
LINC AP 2016, Hong Kong A.Z. Sint-Blasius, Dendermonde Marc Bosiers Koen Deloose Joren Callaert Imelda Hospital, Bonheiden Drug delivery devices for BTK treatment Patrick Peeters Jürgen Verbist W. Van
Update on the Ranger clinical trial programme
Update on the Ranger clinical trial programme Dierk Scheinert, MD Universitätsklinikum Leipzig, Leipzig, Germany on behalf of the RANGER SFA investigators Disclosure Speaker s name: Dierk Scheinert I have
Atherectomy is Still Live and Effective. John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center UC Davis Health System
Atherectomy is Still Live and Effective John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center UC Davis Health System Why is Atherectomy Still Alive? Improved devices Better data
RANGER SFA REGISTRY Interim Analysis. Bernd Gehringhoff, MD On behalf the Ranger SFA Registry Investigators
RANGER SFA REGISTRY Interim Analysis Bernd Gehringhoff, MD On behalf the Ranger SFA Registry Investigators Conflict of Interest - Disclosure Within the past 12 months, I or my spouse/partner have had a
THE SCIENCE BEHIND DRUG COATED BALLOONS OUTCOMES
THE SCIENCE BEHIND DRUG COATED BALLOONS OUTCOMES THE IDEA AND THE TECHNOLOGY FRANCESCO JATTA, PH.D. PROGRAM MANAGER DISCLOSURES I have the following potential conflicts of interest to report: Consulting
EffPac - Trial: Assessment of the Effectiveness of DCB versus POBA in the SFA Ulf Teichgräber, MD, MBA
EffPac - Trial: Assessment of the Effectiveness of DCB versus POBA in the SFA Ulf Teichgräber, MD, MBA Leipzig, 24.01.2017 Prof. Dr. Ulf Teichgräber - LINC 2017 2 Disclosure of conflict of interest Speaker
Drug-coated balloons in BTK:
Drug-coated balloons in BTK: Where do we stand and what are the open questions? Dr. Marc Bosiers LINC 2019 - Leipzig My disclosures x o I do not have any potential conflicts of interest to report o I have
Recent Advances in Peripheral Salvage
Recent Advances in Peripheral Salvage Dr Shaiful Azmi Yahaya, MD, MMed, FNHAM, FAsCC, FAPSIC Consultant Cardiologist and Peripheral Interventionist, Institut Jantung Negara Disclosure I am proctoring for
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
Why and where do I use mechanical debulking for the treatment of arterial occlusions?
Why and where do I use mechanical debulking for the treatment of arterial occlusions? Prof. Thomas Zeller Department Angiology University Heart-Center Freiburg - Bad Krozingen Bad Krozingen, Germany Faculty
Current Status of DCB Experience with Non- Femoropopliteal Applications (Dialysis, Tibial, Venous)
Current Status of DCB Experience with Non- Femoropopliteal Applications (Dialysis, Tibial, Venous) Saher Sabri, MD University of Virginia Health System Charlottesville, Virginia Dialysis vascular access
Future Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit?
Future Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit? John R. Laird Adventist Heart and Vascular Institute St. Helena, CA Disclosure Speaker name: John R. Laird... I have
The Evidence for Drug Coated Balloons Below The Knee:
The Evidence for Drug Coated Balloons Below The Knee: Dr Sumaira Macdonald MBChB (Comm.), FRCP, FRCR, PhD, EBIR Consultant Vascular Radiologist & Honorary Clinical Senior Lecturer, Freeman Hospital, Newcastle,
Rotarex mechanical debulking: The Leipzig experience in patients
Rotarex mechanical debulking: The Leipzig experience in 1.200+ patients Dierk Scheinert, MD Division of Interventional Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Dierk Scheinert
Evolving Role of Drug-Eluting Stents In Complex SFA - Majestic Trial Data
Evolving Role of Drug-Eluting Stents In Complex SFA - Majestic Trial Data Ralf Langhoff, MD Center for Vascular Medicine Berlin-Wilmersdorf St. Gertrauden Hospital Charité, CC11 Academic Teaching Hospitals
ESVB State of the art: DES, DCB and the role of debulking. Gunnar Tepe, Rosenheim
ESVB 2013 State of the art: DES, DCB and the role of debulking Gunnar Tepe, Rosenheim DES I Sirocco Sirolimus coating, quick release Duda et al., J Vasc Surg 2002; 106: 1505-1509 20 DES II Strides Everolimus
Alternative concepts for drug delivery in BTK arteries the LIMBO project
Alternative concepts for drug delivery in BTK arteries the LIMBO project Dierk Scheinert, MD Division of Interventional Angiology University Hospital Leipzig, Germany 1 Disclosure Speaker s name: Dierk
Neuestes aus der Therapie der pavk. beschichtete Stents + Ballons. Karls-University. Eberhard-Karls. of Tubingen Department of Diagnostic Radiology
Eberhard-Karls Karls-University of Tubingen Department of Diagnostic Radiology Neuestes aus der Therapie der pavk Berlin Dezember 08 beschichtete Stents + Ballons Gunnar Tepe 1 Local Drug Delivery Basic
Drug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND
Drug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND Drug eluting stents and balloons Endovascular treatment now becoming more popular for treatment
ISR-treatment The Leipzig experience with purely mechanical debulking. Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany
ISR-treatment The Leipzig experience with purely mechanical debulking Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich I have the following
A Data-driven Therapeutic Algorithm For Choosing Among Currently Available Tools For SFA Intervention
A Data-driven Therapeutic Algorithm For Choosing Among Currently Available Tools For SFA Intervention William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia
Cutting/scoring balloon Cryoplasty Drug-eluting balloon Brachytherapy Debulking Restent (BMS or DES) John R. Laird, MD
Current Treatment of Femoropopliteal Instent Restenosis Professor of Medicine Medical Director of the Vascular Center UC Davis Medical Center SFA In-stent Restenosis Common: 18%- 40% at 12 months in recent
Surgical Bypass vs. Zilver PTX stent for long SFA lesions : Interim results of the ZilverPass Trial
Surgical Bypass vs. Zilver PTX stent for long SFA lesions : Interim results of the ZilverPass Trial Dr. Koen Deloose Head of Vascular Surgery AZ Sint-Blasius Dendermonde Belgium Disclosure slide Speaker
Lutonix DCB in BTK Update on the BTK real world registry and RCT
Lutonix DCB in BTK Update on the BTK real world registry and RCT Prof. Dr. med. Dierk Scheinert Department of Interventional Angiology University Hospital Leipzig Disclosures Speaker: Prof. Dr. med. Dierk
Superficial Femoral Artery Intervention: The gift that keeps on giving! Wm. Britton Eaves,MD WKHSC Bossier City, LA
: The gift that keeps on giving! Wm. Britton Eaves,MD WKHSC Bossier City, LA Peripheral arterial disease (PAD) of the superficial femoral artery (SFA) is the most common cause of intermittent claudication
SFA In-stent Restenosis
Disclosure In-Stent Restenosis: Endo-Salvage Works for Most Patients Peter A. Schneider, MD Hawaii Permanente Medical Group and Kaiser Foundation Hospital Honolulu, Hawaii Peter A. Schneider Potential
Role of Covered Stents and Drug Eluting Balloons In Dialysis Access
Role of Covered Stents and Drug Eluting Balloons In Dialysis Access Joseph Habib, MD, FACS Assistant Professor Department of Surgery Division of Vascular and Endovascular Surgery University of Florida
TOBA II 12-Month Results Tack Optimized Balloon Angioplasty
TOBA II 12-Month Results Tack Optimized Balloon Angioplasty William Gray, MD System Chief, Cardiovascular Division Main Line Health, Philadelphia, PA Dissection: The Primary Mechanism of Angioplasty Lesions
Drug Elution, Data, and Decisions
Drug Elution, Data, and Decisions What the data tell us about how to integrate drug-eluting technology into our daily practice. BY GARY ANSEL, MD, AND JOHN A. PHILLIPS, MD The use of drug-eluting technology
Management of In-stent Restenosis after Lower Extremity Endovascular Procedures
Management of In-stent Restenosis after Lower Extremity Endovascular Procedures Piotr Sobieszczyk, MD Associate Director, Cardiac Catheterization Laboratory Cardiovascular Division and Vascular Medicine
The Lutonix BTK Clinical Trial Programme: Status Update and Real World Clinical Experience
The Lutonix BTK Clinical Trial Programme: Status Update and Real World Clinical Experience Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany Disclosure Speaker name: Dierk Scheinert I have
The BATTLE Trial Comparing Bare Metal to Drug Eluting Stents for Intermediate Length Lesions of the SFA
The BATTLE Trial Comparing Bare Metal to Drug Eluting Stents for Intermediate Length Lesions of the SFA BATTLE RCT investigators: Y. Gouëffic, A. Sauguet, P. Desgranges, P. Feugier, E. Rosset, E. Ducasse,
12-Month and preliminary 24-month outcomes of combining a DCB with a modern generation of nitinol stent in fem-pop lesions. BIOLUX 4EVER study
12-Month and preliminary 24-month outcomes of combining a DCB with a modern generation of nitinol stent in fem-pop lesions BIOLUX 4EVER study Dr. Lieven Maene OLV Aalst, Belgium Disclosure slide Speaker
January 23, Vascular and oncological interventional radiology Paris Descartes University
January 23, 2019 First time data release: Paclitaxel-coated balloon in below-the-knee lesions: 6-months results from the Ranger BTK single center study Dr. Costantino Del Giudice Prof Marc Sapoval Vascular
MICHAEL R. JAFF, DO MASSACHUSETTS, UNITED STATES. Medtronic Further. Together
DRUG-COATED BALL0ON TREATMENT FOR PATIENTS WITH INTERMITTENT CLAUDICATION: INSIGHTS FROM THE IN.PACT GLOBAL FULL CLINICAL COHORT MICHAEL R. JAFF, DO MASSACHUSETTS, UNITED STATES Medtronic Further. Together
REACT Treatment Rationale and Clinical Evidence. ICI Meeting 5th of December 2017
REACT Treatment Rationale and Clinical Evidence ICI Meeting 5th of December 2017 The SFA is a challenging vessel to treat Shortening 23-25%1 Compression > 1kg2 Torsion 60 3 Bending 64 4 SFA, superficial
New Drug Coated Balloons in Femoro-Popliteal Disease in Korea
New Drug Coated Balloons in Femoro-Popliteal Disease in Korea Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC Div of Cardiovascular Intervention and Research Cardiovascular Center, Korea University
Contemporary use of DCBs, Ranger clinical trial and investigator sponsored research
Contemporary use of DCBs, Ranger clinical trial and investigator sponsored research Dierk Scheinert, MD Division of Interventional Angiology University-Hospital, Leipzig, Germany IMPORTANT INFORMATION:
The latest generation DEB
The latest generation DEB V. Riambau, MD. PhD Prof. and Chief of Vascular Surgery Division, Cardiovascular Institute, Hospital Clínic of Barcelona University of Barcelona Consultant: Bolton Medical/ Medtronic/
Robert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015
Robert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015 Disclosure I have nothing to disclose Randomized Controlled Studies In SFA Technology: What s The Best Tool For
Vessel Preparation: What does it mean and what are the current tools? Lawrence Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA
Vessel Preparation: What does it mean and what are the current tools? Lawrence Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA Disclosure Statement of Financial Interest Within the past 12 months,
Clinical use and safety of the Lutonix DCB for the treatment of BTK: interim data from a prospective registry
Clinical use and safety of the Lutonix DCB for the treatment of BTK: interim data from a prospective registry Alexander Zimmermann Department of Vascular and Endovascular Surgery Klinikum rechts der Isar
The drug-eluting balloon superficial femoral artery-long study THE DEB SFA-LONG STUDY
The drug-eluting balloon superficial femoral artery-long study THE DEB SFA-LONG STUDY Safety and efficacy of the Drug Eluting Balloon (DEB) for the treatment of the Superficial Femoral Artery (SFA) ischemic